Atlas FDA

Predicate Research Report · generated 2026-08-22 · Print / save as PDF · Save to account

Neuronetics, Inc. — Predicate Candidate Screening

8 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.

178 daysmedian FDA review time
289 days90th percentile
8clearances measured
K-numberDeviceApplicantDecidedReview daysRecalls (K-match)
K231926NeuroStar Advanced Therapy System (All previously cleared moNeuronetics, Inc.2024-03-222660
K222230NeuroStar, NeuroStar TMS Therapy System, NeuroStar Advanced Neuronetics, Inc.2022-08-24300
K220127NeuroStar TMS Therapy System, NeuroStar Advanced Therapy SysNeuronetics, Inc.2022-07-151780
K212289NeuroStar Advanced Therapy for adjunctive treatment of OCD, Neuronetics, Inc.2022-05-062890
K213543NeuroStar TMS Therapy System, NeuroStar Advanced Therapy SysNeuronetics, Inc.2021-12-10320
K201158NeuroStar Advanced TherapyNeuronetics, Inc.2020-11-202040
K161519NeuroStar TMS Therapy SystemNeuronetics, Inc.2016-09-111010
K160703NeuroStar TMS Therapy SystemNeuronetics, Inc.2016-06-10880

Methodology

Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.

Prepared with Atlas

Predicate research, review-time statistics and recall monitoring for 510(k) teams — atlasbyauro.com/fda